Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women was written by Simon, James;Portman, David;Mabey, R. Garn. And the article was included in Maturitas in 2014.Computed Properties of C24H23ClO2 This article mentions the following:
Objective: To examine the long-term safety of oral ospemifene, a non-estrogen tissue-selective estrogen agonist/antagonist, for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA) due to menopause. Study design: This multicenter, long-term, open-label, safety extension study was conducted in women without a uterus aged 40-80 years (N = 301) who received oral ospemifene 60 mg/day for 52 wk. Participants either continued their 60-mg/day ospemifene dose from the initial 12-wk pivotal efficacy study or switched from blinded placebo or ospemifene 30 mg/day to open-label ospemifene 60 mg/day. The 52-wk open-label extension period plus initial 12-wk treatment period totaled up to 64 wk of ospemifene exposure. A 4-wk posttreatment follow-up ensued (68 wk total). Main outcome measures: Safety assessments included adverse events, laboratory studies, phys. and gynecol. examination, vital signs, breast palpation, and mammog.Most treatment-emergent adverse events (TEAEs) during the extension study were mild or moderate in severity. The most common TEAE related to study drug was hot flushes (10%; leading to discontinuation for 2% of patients). One serious TEAE, a non-ST-elevation myocardial infarction in a patient with pre-existing cardiac disease, was considered possibly related to study medication. One mild breast-related TEAE, considered unrelated to study drug, was ongoing at study completion. There were no instances of pelvic organ prolapse, incontinence, venous thromboembolism, fractures, breast cancers or death. No clin. significant adverse changes were observed in other safety parameters. Conclusions: Ospemifene is clin. safe and generally well tolerated in postmenopausal patients with dyspareunia, a symptom of VVA. In the experiment, the researchers used many compounds, for example, (Z)-2-(4-(4-Chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)ethan-1-ol (cas: 128607-22-7Computed Properties of C24H23ClO2).
(Z)-2-(4-(4-Chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)ethan-1-ol (cas: 128607-22-7) belongs to alcohols. Alkyl halides are often synthesized from alcohols, in effect substituting a halogen atom for the hydroxyl group. Grignard and organolithium reagents are powerful tools for organic synthesis, and the most common products of their reactions are alcohols.Computed Properties of C24H23ClO2
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts